About this trial
Squamous cell carcinoma (SCC) could be a very aggressive cancer and has a bad prognosis if not detected early and thus is associated with high mortality. The development of simple and reliable biomarkers for the early detection of SCC is one of the solutions to better diagnose, treat these tumors, evaluate and monitor treatments, and hence reduce mortality. In a previous work, the investigators demonstrated the ability of Proton Magnetic resonance spectroscopy (1H-MRS) to non-invasively assess spectroscopic and metabolic profiles of tongue tissue in healthy subjects. In the present work, the investigators challenge the use of in-vivo 1H-MRS as a potential method for non-invasive metabolic monitoring of patients with squamous cell carcinoma of the tongue undergoing therapy. Thus the main objective is to study the spectroscopic and metabolic differences, e.g. including variation in the metabolite TMA-Cho (trimethylamine-choline), of tongue tissue between healthy subjects and in patients with squamous cell carcinoma of the tongue, before and after surgery.
Eligibility criteria
Qualifiers
Patients from the maxillofacial surgery department of the Amiens-Picardie University Hospital treated for histologically confirmed squamous cell carcinoma of the tongue
Patients who have not yet been treated, either surgically or by neoadjuvant treatment
Patients with a tumor of minimum dimensions of 15 mm in long axis
Patients without contraindication to MRI
Disqualifiers
Patients with a lingual tumor measuring less than 15 mm in long axis
Patients with other histological types of cancer, or other locations
Subjects with a contraindication to MRI
Subjects under 18 years old
Trial design
Treatments tested in this trial
- MRI and MRS acquisitions
Treatment groups
Sponsors and collaborators
Centre Hospitalier Universitaire, Amiens
Lead sponsor
Groupe Hospitalier Pitie-Salpetriere
Collaborator